Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. November 2017 09:45 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV

PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D.,...
15. November 2017 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Nine Months Ended September 30, 2017

PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) announced today its financial results for the third quarter ended September 30, 2017. The net loss was $1.3...
15. August 2017 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017

The Company has Generated Revenues and Advanced in R&D for Intranasal Ampligen and in Immuno-Oncology Conference Call Scheduled for Tuesday, August 15th at 1:00 PM EDT PHILADELPHIA, Aug. 15,...
14. August 2017 08:30 ET | Quelle: LinkedIn

Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated

PHILADELPHIA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist®...
11. August 2017 10:20 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017

PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2017 second quarter financial...
08. August 2017 06:08 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

PHILADELPHIA, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian...
04. August 2017 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome

PHILADELPHIA, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may provide the basis for a...
10. Juli 2017 08:30 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer

PHILADELPHIA, July 10, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen...
31. Mai 2017 12:03 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to bolster its scientific capabilities by...
31. Mai 2017 11:38 ET | Quelle: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...

Vorherige Seite

Nächste Seite